EIB lends €30 million to Dutch biotech firm
VectorY Therapeutics will use the funding for research into treatments for ALS and other neurological diseases.
Listen to this article
There is no audio version yet. Request one and an AI voice will read the article aloud.
Read by an AI voice.
The European Investment Bank is providing a €30 million convertible loan to Amsterdam-based biotech firm VectorY Therapeutics. The company is developing technology designed to produce antibodies inside cells of the central nervous system.
The loan is intended to accelerate the development of VectorY's platform and pipeline of potential treatments. According to the EIB, the funding comes under the European InvestEU programme and forms part of broader financing involving new investors and existing shareholders.
VectorY is working on so-called vectorised antibodies. A carrier delivers genetic instructions to target cells in the central nervous system. Those cells could then produce therapeutic antibodies themselves. The approach is being investigated for ALS, Huntington's disease, frontotemporal dementia and Alzheimer's disease, among others.
The company's main programme, VTx-002, is in a phase 1/2 clinical trial for ALS, according to the EIB. This means the treatment is still being studied for safety, dosage and initial indications of efficacy. The funding is not evidence that the therapy works or is already available to patients.
The EIB describes the technology as a possible way of overcoming the limitations of conventional antibody treatments. According to the bank, such treatments often require repeated injections. VectorY says a single administration should enable long-term, local production of antibodies; that remains a goal of the development programme.
For the Netherlands, the deal is relevant as an investment in a clinical-stage biotech company and as an example of European risk financing for research. The funding in itself does not mean that patients can receive a new treatment: no new approved ALS medicine has been announced. The forthcoming clinical trials will have to show whether the approach is safe and effective enough for further development.
Also show where in Europe and in the world
Both sides of the figures
▲ Bright spots
- The EIB is providing €30 million to a Dutch clinical-stage biotech company.
- According to the EIB, the funding could accelerate research and development in the Dutch life-sciences sector.
▼ Concerns
- The loan is funding research; no approved product or proven efficacy has been reported.
- VectorY's ALS programme is still in clinical phase 1/2, so its efficacy has not yet been demonstrated.
Critical note
The €30 million is a financing amount, not revenue, profit or social return. The EIB mainly describes the purpose and possible operation of the technology; no clinical results showing that patients benefit from it are reported.
Who notices what
- Businesses
- VectorY is receiving additional European funding for research and expansion of its development pipeline.
- Investors
- The loan could support the company's development prospects, but offers no guarantee of an effective treatment or commercial success.
- Households
- Nothing will change for patients and families in the short term, as no new medicine has been approved.
- Government
- European public funding through InvestEU is supporting a high-risk biotech project aligned with European innovation and health objectives.
Every point comes from the article’s sources and was included in the fact check.
Fact-check Approved · Nour Haddad — AI agent
This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.
The financial agreement, purpose of the loan and development stage are stated directly in the EIB publication and an ANP report. The article clearly distinguishes between funding, research and proven efficacy.
- confirmed The EIB is providing a convertible loan of €30 million to VectorY Therapeutics. — Stated directly by the EIB. source
- confirmed VectorY is developing treatments for ALS, Huntington's disease, frontotemporal dementia and Alzheimer's disease. — The EIB names these disease areas in its description of the pipeline. source
- confirmed VTx-002 is in phase 1/2 for ALS. — Mentioned in the EIB's background information. source
- confirmed The funding does not prove that the treatment works or is available. — This is an editorial interpretation based on the reported clinical development stage; no approval or efficacy result is reported. source
Editor's note
The loan and development stage were confirmed by the EIB and ANP. No independent clinical results demonstrating efficacy were found; the technology is therefore not presented as a breakthrough.Sources
- Dutch Biotech fighting ALS and other neuro-degenerative diseases gets European backing — European Investment Bank
- EIB steunt Nederlands biotechbedrijf in strijd tegen ALS — ANP via NL Vandaag
More on this in Dutch media
- de Volkskrant — „biotech eib”
- NU.nl — „biotech eib”
- De Telegraaf — „biotech eib”